导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -16.09% | 4163/4773 |
| 近一周 | -2.34% | 3743/5465 |
| 近一月 | 0.01% | 699/5421 |
| 近一季 | -8.98% | 3465/5231 |
| 近半年 | -18.68% | 4311/4920 |
| 近一年 | -2.86% | 3079/4394 |
| 近两年 | 42.90% | 1779/2954 |
| 近三年 | 11.89% | 1707/2253 |
| 成立以来 | 45.11% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.98% 3738/4961 |
-1.99% 3380/5312 |
- - |
- - |
| 2025 | 31.50% 1233/4813 |
-1.85% 2799/3635 |
11.86% 129/4076 |
7.63% 3443/4524 |
11.28% 172/4813 |
| 2024 | 8.33% 1566/3463 |
-6.30% 2040/2808 |
-2.32% 1175/3014 |
13.12% 2237/3129 |
4.62% 686/3463 |
| 2023 | -10.82% 1341/2656 |
1.16% 1628/2280 |
3.13% 108/2385 |
-10.74% 2018/2515 |
-4.23% 921/2655 |
| 2022 | -26.29% 1387/2207 |
-22.71% 1711/1919 |
3.75% 1097/2016 |
-7.49% 130/2113 |
-0.64% 1634/2208 |
| 2021 | 14.39% 333/1822 |
-18.80% 1207/1255 |
10.47% 460/1330 |
7.86% 172/1466 |
18.22% 37/1822 |
| 2020 | 70.91% 68/1250 |
-0.85% 194/1028 |
11.73% 717/1067 |
30.29% 12/1164 |
18.41% 93/1184 |
| 2019 | 26.48% 573/1092 |
33.09% 147/754 |
-9.17% 635/804 |
5.55% 145/850 |
-0.88% 892/918 |
| 2018 | -26.28% 379/834 |
- - |
- - |
- - |
-13.31% 526/691 |
| 2017 | -14.60% 560/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 广发中证军工ETF VS. 长安沪深300非周期A(740101) |